Raltegravir (MK-0518)

Name: Raltegravir (MK-0518)
Brand: Selleck Chemicals
SKU: S2005
Rating: 5 (47 reviews)

For research use only.

Catalog No.S2005

47 publications

Raltegravir (MK-0518) Chemical Structure

CAS No. 518048-05-0

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. It shows greater than 1000-fold selectivity for HIV-1 IN over several related Mg2+-dependent enzyme such as HCV polymerase, HIV reverse transcriptase, HIV RNaseH and human α-, β-, γ-polymerases.

Selleck's Raltegravir (MK-0518) has been cited by 47 publications

Cancer Cell, 2019, 36(4):385-401

PubMed: 31564637 ( click the link to review the publication )

Nature, 2016, 530(7590):358-61

PubMed: 26887496 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(10)e2005568118

PubMed: 33649200 ( click the link to review the publication )

PLoS Pathog, 2021, 17(5):e1009577

PubMed: 34019588 ( click the link to review the publication )

Int J Nanomedicine, 2021, 16:1189-1206

PubMed: 33623382 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

J Virol, 2020, JVI.01386-20

PubMed: 33298546 ( click the link to review the publication )

J Virol, 2020, JVI.01247-20

PubMed: 33239456 ( click the link to review the publication )

Blood Adv, 2020, 12;4(9):1845-1858

PubMed: 32369565 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

J Virol, 2019, 93(9)

PubMed: 30760577 ( click the link to review the publication )

JCI Insight, 2019, 4(12)

PubMed: 31217351 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3450

PubMed: 30150664 ( click the link to review the publication )

Elife, 2018, 7e36245

PubMed: 29941091 ( click the link to review the publication )

Mol Ther, 2018, 26(6):1435-1446

PubMed: 29724686 ( click the link to review the publication )

mBio, 2018, 9(6)

PubMed: 30401776 ( click the link to review the publication )

PLoS Pathog, 2018,

PubMed: 29470552 ( click the link to review the publication )

J Infect Dis, 2018, 218(11):1773-1776

PubMed: 30010985 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Virol J, 2018, 15(1):152

PubMed: 30285810 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(3):392-404

PubMed: 30173955 ( click the link to review the publication )

J Clin Invest, 2017, 127(12):4352-4364

PubMed: 29083319 ( click the link to review the publication )
Cell Rep, 2017, 18(5):1324-1334

PubMed: 28147284 ( click the link to review the publication )

Cell Death Dis, 2017, 8(6):e2852

PubMed: 28569776 ( click the link to review the publication )

J Virol, 2017, 91(24)

PubMed: 29021396 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(8)

PubMed: 28533248 ( click the link to review the publication )

Wellcome Open Res, 2017, 2:87

PubMed: 29062917 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(14):6896-906

PubMed: 27369381 ( click the link to review the publication )

Front Microbiol, 2016, 7:1944

PubMed: 27990142 ( click the link to review the publication )

Bioorg Med Chem, 2016, 24(11):2410-22

PubMed: 27117260 ( click the link to review the publication )

Sci Signal, 2015, 8(399):ra104

PubMed: 26486173 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 10.1128/AAC.00114-15

PubMed: 25779572 ( click the link to review the publication )

Virology, 2015, 484:364-76

PubMed: 26186575 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(6):3168-76

PubMed: 24663015 ( click the link to review the publication )

Antimicrob Agents Chemother., 2014, 58(8):4431-42

PubMed: 24867983 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105617

PubMed: 25144636 ( click the link to review the publication )

PLoS Pathog, 2013, 9(1):e1003125

PubMed: 23349632 ( click the link to review the publication )

J Virol, 2013, 87(17):9768-79

PubMed: 23824795 ( click the link to review the publication )

Retrovirology, 2013, 10:144

PubMed: 24261564 ( click the link to review the publication )

PLoS One, 2013, 8(11):e81489

PubMed: 24282600 ( click the link to review the publication )

Sci Rep, 2013, 3:2103

PubMed: 23812503 ( click the link to review the publication )

Blood, 2012, 120(17):3488-90

PubMed: 22955925 ( click the link to review the publication )

J Virol, 2012, 86(17):9337-50

PubMed: 22718820 ( click the link to review the publication )

Virus Res, 2012, 171(1):121-8

PubMed: 23201205 ( click the link to review the publication )

Vet Microbiol, 2011, 152(1-2):165-8

PubMed: 21570781 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Integrase Inhibitors

Biological Activity

Description

Features

The 1st approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor.

Targets

Integrase (S217Q PFV) ^[1] (Cell-free assay)	Integrase (WT PFV) ^[1] (Cell-free assay)
40 nM	90 nM

In vitro

PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM, indicating a ~twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme. ^[1] Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31?0 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95 of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity. ^[2] Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium. ^[3] Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication. ^[4] In acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
MT4	NH7QS5VCdnSrdnnyZYwh[XO\|YYm=			MVLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25uIFXDOVAhRSByLkCwNVQh\|ryPLh?=	NFX3fpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW0NVczPid-MUi1OFE4OjZ:L3G+
MT-4	Mn7ERY51cX[rcnHsJIF{e2G7			MnvjRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UMVQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjygSWM2OCB;IECuNFAyQCEQvF2u	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDF4MEWyNUc,OThzNkC1NlE9N2F-
MT-4	MUDBcpRqfmm{YXygZZN{[Xl?			NV:zcm5ySW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhfmW\|aXP1cIFzKHO2b33heIl1cXNidnnyeZMhTy2yc3X1[I91gXCnZDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJIlv\mWldHXkJIlvKGi3bXHuJG1VNTRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckwhTUN3MDC9JFAvODB{IN88UU4>	Mli1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThzNkC1NlEoRjF6MU[wOVIyRC:jPh?=
MT2	NFOzTHhCdnSrdnnyZYwh[XO\|YYm=		M2PCRVMhfG9iNDDkZZl{	NF;aUppCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKE2WMjDj[YxteyCvZXHzeZJm\CCjZoTldkA{KHSxIESg[IF6eyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjByMjFOwG0v	M2XkSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN{MEixNFExLz5\|MkC4NVAyODxxYU6=
MT-2	M1rJVmFvfGm4aYLhcEBie3OjeR?=			M{fvNmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQuOiClZXzsd{BjgSC2d3:g[o9t\CCmaXz1eIlwdiCvZYToc4QhcW5icILld4Vv[2Vib3[gNVAmKE[EUzygSWM2OCB;IECuNFA{KM7:TT6=	MoTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMESwNVAoRjF7MUC0NFExRC:jPh?=
MT2	MUnBcpRqfmm{YXygZZN{[Xl?		M13qR\|Uh\GG7cx?=	NVfFSlRbSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDJiY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JINp\W2rbIXtbY5me2OnbnPlJIlvKHC{ZYPlcoNmKG:oIH\leIFtKGKxdnnu[UB{\XK3bTygSWM2OCB;IECuNFA1KM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ6NUO4PUc,OTl{OEWzPFk9N2F-
HOS	NH7pOm1CdnSrdnnyZYwh[XO\|YYm=			MWnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGijcnLvdolv\yC5aXzkMZR6eGViaX70[Ydz[XOnIHnu[oVkfGWmIHnuJIh2dWGwIFjPV{Bk\WyuczygSWM2OCB;IECuNFA1KM7:TT6=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR7M{C2Okc,OjF2OUOwOlY9N2F-
HOS	MnLCRY51cX[rcnHsJIF{e2G7		M2\U[FMhcHK\|	MY\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDD3bYxlNXS7cHWgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKGmwZnXjeIVlKGmwIFjPV{Bk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEOgbJJ{KG[xbHzve4VlKGK7II\pdoFtKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxKD1iMD6wNFQh\|ryPLh?=	NUC4NGNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E5OTZpPkK0OFcyQDF4PD;hQi=>
MT2	M2TJTWFvfGm4aYLhcEBie3OjeR?=		NV;ZPHF5PSCmYYnz	MWLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnuJG1VOiClZXzsd{Bi\nSncjC1JIRigXNuIFXDOVAhRSByLkCwOkDPxE1w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJyN{O5PEc,OTh{MEezPVg9N2F-
MT-4	MXfBcpRqfmm{YXygZZN{[Xl?			MnfqRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXKDFiUlnOJIhiemKxcnnu[{BqdnSnZ4Lhd4Uh\2WwZTDpcoZm[3SnZDDpckBOXC12IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUCgQUAxNjByNjFOwG0v	NYXqZldzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|g4OTNpPkG4N\|c5PzF\|PD;hQi=>
MT4	NFLKNo5CdnSrdnnyZYwh[XO\|YYm=			MnvRRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFA3KM7:TT6=	NInjRpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFcyQCd-MkS5NFA4OTh:L3G+
MT4	M4HYd2FvfGm4aYLhcEBie3OjeR?=			NWHnZ3o6SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYLUGgN2IhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDyc5Rm[3Srb36gZYdicW6\|dDD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFA3KM7:TT6=	NV7uO3ZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PVM{PjBpPkK0O\|k{OzZyPD;hQi=>
MT4	MYDBcpRqfmm{YXygZZN{[Xl?			NYD0[HJmSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|IHnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RuIFXDOVAhRSByLkCwOlEh\|ryPLh?=	NFrt[5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES3PVIxPid-MkC0O\|kzODZ:L3G+
MT4	MW\GeY5kfGmxbjDhd5NigQ>?		M1v0elEhcHJ?	M2PnR2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFjJWlEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IIXzbY5oKGOnbHzzJJBz\S2rbnP1ZoF1\WRid3n0bEBkd22yb4Xu[EBnd3JiMTDodkBu\WG\|dYLl[EA1KGSjeYOgdI9{fCC4aYLhcEBqdm[nY4Tpc44h[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNFYzKM7:TT6=	NHvMXVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm2N\|E{PSd-MkK5OlMyOzV:L3G+
MT4	NHTibGNCdnSrdnnyZYwh[XO\|YYm=			MULBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bI9o\W6rY3n0fUBjgSCPVGSgZZN{[XluIFXDOVAhRSByLkCwOlQh\|ryPLh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR2N{[yNUc,OTl2NEe2NlE9N2F-
MT-4	M4\2d2FvfGm4aYLhcEBie3OjeR?=			NWm0Omo6SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYIEGgUmw1NjNiaHHyZo9zcW6pIHnueIVoemG\|ZTDMO\|ROKG23dHHueEBqdm[nY4Tl[EBqdiCqdX3hckBOXC12IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUCgQUAxNjByNzFOwG0v	NEmxO249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3PFcyOyd-MUizO\|g4OTN:L3G+
MT4	MnXvRY51cX[rcnHsJIF{e2G7			NVjUNoJbSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbD3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODB5ODFOwG0v	MmTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NUGwPVUoRjJ6OUWxNFk2RC:jPh?=
MT-4	MV3BcpRqfmm{YXygZZN{[Xl?			MkPJRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpcoZm[3SnZDDpckBpfW2jbjDNWE01KGOnbHzzJIJ6KHS5bzDmc4xlKGSrbIX0bY9vKG2ndHjv[EBqdiCycnXz[Y5k\SCxZjCxNEUhTkKVLDDFR\|UxKD1iMD6wNFgh\|ryPLh?=	MornQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMESwNVAoRjF7MUC0NFExRC:jPh?=
MT-4	NHXYeGJCdnSrdnnyZYwh[XO\|YYm=			NFW3VWRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZiMTDOUFQvOyCrboTl[5Jie2ViU{KzNG4hdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJG1VNTRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODB7IN88UU4>	NU\EN5JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|g4OTNpPkG4N\|c5PzF\|PD;hQi=>
MT4	NW\QdWxGSW62aY\pdoFtKGG\|c3H5		NEjKfIU1QCC2bzC3NkBpenN?	M{jQeWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHX4dJJme3OrbnegS2ZRKGmwY4XiZZRm\CCob4KgOFghfG9iN{KgbJJ{KGmwIHHid4Vv[2Vib3[gOVAmKG6xcn3hcEBpfW2jbjDz[ZJ2dSCkeTDteYx1cXCuZTDyc5Vv\CC4aYLhcEBz\XCuaXPheIlwdiCtaX7leIlkeyCjc4PhfUwhUVBiPTCwMlAxQSEQvF2u	NIm1SnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|k3PSd-Mk[zPVc6PjV:L3G+
FL-4	M{DTXGFvfGm4aYLhcEBie3OjeR?=			MV\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDG[YxqdmViaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{Bqdm[nY4Tl[EBqdiClYYSgSmwuPCClZXzsd{Bie3Onc4Pl[EBieyC4aYLhcEBTVkFicILv[JVkfGmxbjDifUBTXC2zUFPSMEBGSzVyIE2gNE4xODl7ODFOwG0v	MlLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUO3N\|IoRjJ2OEGzO\|MzRC:jPh?=
MT-4	NFfU[HBCdnSrdnnyZYwh[XO\|YYm=			MW\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYhOSCUSV6gbIFz[m:{aX7nJIlvfGWpcnHz[UBo\W6nIHnu[oVkfGWmIHnuJG1VNTRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUBi\nSncjCyNEBx[XO\|YXfld{B{\WynY4Tl[EBqdiCycnXz[Y5k\SCxZjDjc41xd3WwZDygSWM2OCB;IECuNFEh\|ryPLh?=	NH;RbmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3PFcyOyd-MUizO\|g4OTN:L3G+
HeLa	MWnBcpRqfmm{YXygZZN{[Xl?		Ml7DOFghcHK\|	MV\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDWV3YuTyCyc3X1[I91gXCnZDDITXYyKGynboTpeolz[WxicHHyeIlkdGW\|IHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nlic4DlZ5Rzd2[udX;yc41mfHK7LDDJR\|UxKD1iMD6wNUDPxE1w	NFLIXFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki1PFMxOCd-MkK4OVg{ODB:L3G+
cat FL-4	NH;ndFBCdnSrdnnyZYwh[XO\|YYm=		MnPqO{Bl[Xm\|	NUTXZmQ{SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhTmWuaX7lJIludXWwb3Tl[olkcWWwY4mgeolzfXNiaX7m[YN1\WRiaX6gZ4F1KE[OLUSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCjZoTldkA4KGSjeYOgZpkheXWjboTpeIF1cX[nIGLUMXBEWiCjbnHsfZNqeyxiRVO1NEA:KDBwMEGg{txONg>?	MkLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEK4OFkoRjJ3N{CyPFQ6RC:jPh?=
cat FL-4	M{nTSGFvfGm4aYLhcEBie3OjeR?=		MnH5O{Bl[Xm\|	NH7sdI1CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBHUVZiaX7m[YN1\WRiaX6gZ4F1KE[OLUSgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKH[rcnHsJHJPSSCuZY\lcEBu\WG\|dYLl[EBi\nSncjC3JIRigXNiYomgdXJVNVCFUjDhcoFtgXOrczygSWM2OCB;IECuNFEh\|ryPLh?=	M3y0d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzM{m1OVExLz5\|MUO5OVUyODxxYU6=
MT4	MX3BcpRqfmm{YXygZZN{[Xl?			MmjZRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOiCUT1SgN2IhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXytbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDifUBOXFRiYYPzZZktKEWFNUCgQUAxNjBzMTFOwG0v	NXXMRmdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVExQTVpPkK4PVUyODl3PD;hQi=>
MT4	M{DTUWFvfGm4aYLhcEBie3OjeR?=			NXP3TXJCSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIEPCJIlv\mWldHXkJIlvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDwdo91\WO2aX;uJIFo[Wmwc4SgeolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCvZXHzeZJm\CB3IHThfZMheG:\|dDDpcoZm[3Srb36gZpkhVVSWIHHzd4F6NCCHQ{WwJF0hOC5yMUG3JO69VS5?	MknWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NEC0OlIoRjJ7OUSwOFYzRC:jPh?=
MT4	MVzBcpRqfmm{YXygZZN{[Xl?			NVXrZ29MSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuLXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiaX6gbJVu[W5iTWS0JINmdGy\|LDDFR\|UxKD1iMD6wNVMh\|ryPLh?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDRzN{O0Nkc,OTh2MUezOFI9N2F-
MT4	NYP3W2Z2SW62aY\pdoFtKGG\|c3H5			MVXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SsJGVEPTBiPTCwMlAyOyEQvF2u	M{XoelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkOwO\|Y2Lz5{ME[zNFc3PTxxYU6=
MT4	MW\BcpRqfmm{YXygZZN{[Xl?			MYrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7LDDFR\|UxKD1iMD6wNVMh\|ryPLh?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ{N{W1NEc,OjF{Mke1OVA9N2F-
BL21(DE3)	NVvqZoVUTnWwY4Tpc44h[XO\|YYm=		NU\DVIZJOSCqch?=	M1W0dWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGlXNTFiaX70[Ydz[XOnIIP0ZY5lKHS{YX7z[oVzKGGldHn2bZR6KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV\|KTDj[YxteyC3c3nu[{A{OlBvbHHi[Yxm\CCGTlGgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliZHXud4l1d22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvODF\|IN88UU4>	NUPYV2JtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OVE4PzFpPkK2OFUyPzdzPD;hQi=>
MT-4	MlfERY51cX[rcnHsJIF{e2G7			NYPubWozSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYIEGgUmw1NjNiaX70[Ydz[XOnIFW5NnEhdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJG1VNTRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODF3IN88UU4>	M4W3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{e4O\|E{Lz5zOEO3PFcyOzxxYU6=
MT4	MVLBcpRqfmm{YXygZZN{[Xl?		NFTDN5I2KGSjeYO=	MWHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDpcoN2[mG2ZXSg[o9zKDViZHH5d{BjgSCPVGSgZZN{[XluIFXDOVAhRSByLkCxOUDPxE1w	NYTGdnMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzNlQ2PjJpPkOxN\|I1PTZ{PD;hQi=>
MT2	M1XlSWFvfGm4aYLhcEBie3OjeR?=			M1fUNWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXiCrbjDNWFIh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiM{WgcYcwdUxiaIXtZY4he2W{dX2gZYxjfW2rbjygSWM2OCB;IECuNFE3KM7:TT6=	MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{MEezPVgoRjF6MkC3N\|k5RC:jPh?=
MT-4	MVHBcpRqfmm{YXygZZN{[Xl?		NHXwc4I2KGSjeYO=	MnPoRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|Qj;MRWkhcW6oZXP0[YQhcW5iaIXtZY4hVVRvNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgcYVie3W{ZXSgd5Vzfmm4YXygZYZ1\XJiNTDkZZl{KGK7IF3UWEBie3OjeTygSWM2OCB;IECuNFE3KM7:TT6=	NWSxUpFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlQ6OTlpPkK0NVI1QTF7PD;hQi=>
HeLa-CD4-LTR-beta-gal	NFnY[WZCdnSrdnnyZYwh[XO\|YYm=		NWm5OldzOSCmYYm=	NUnP[lY4SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYLUGgN2IhcW6oZXP0[YQhcW5iaIXtZY4hUGWOYT3DSFQuVFSULXLleIEu\2GuIHPlcIx{KGGodHXyJFEh\GG7IHL5JJNx\WO2cn;zZ49xcWNiYX7hcJl{cXNuIFXDOVAhRSByLkCxOkDPxE1w	M2DjVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK5NlU3Lz5{NU[yPVI2PjxxYU6=
MT-2	MVvBcpRqfmm{YXygZZN{[Xl?			NHSyRnFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIlv\mWldHXkJIlvKGi3bXHuJG1VNTJiY3XscJMh[nlidIfvJIZwdGRiZHnseZRqd25ibXX0bI9lKGmwIIDy[ZNmdmOnIH;mJFExLSCIQmOsJGhUSSCjbnSgZYxxcGFzLVHHVEwhTUN3MDC9JFAvODF6IN88UU4>	MnrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMESwNVAoRjF7MUC0NFExRC:jPh?=
MT4	NX25PJdxSW62aY\pdoFtKGG\|c3H5			Mn[0RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpckBpfW2jbjDNWFQh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUClJIhm[XRvYXP0bZZifGWmIH\leIFtKGKxdnnu[UB{\XK3bTygTWM6PSB;IECuNFE6KM7:TT6=	NY\MXHl5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OlM4PTFpPkG4O\|Y{PzVzPD;hQi=>
MT2	NV3ybVRPSW62aY\pdoFtKGG\|c3H5		Ml\POUBl[Xm\|	M{fVTmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQzKGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDjbIVucWy3bXnu[ZNk\W6lZTDpckBxemW\|ZX7j[UBw\iCqdX3hckB{\XK3bTDhcIJ2dWmwLDDFR\|UxKD1iMD6wNkDPxE1w	NV3PR3VqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyPFU{QDlpPkG5Nlg2Ozh7PD;hQi=>
MT4	NFPPZZFCdnSrdnnyZYwh[XO\|YYm=		NYfRemZ7PSCmYYnz	NU\ZWFdNSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMjDSU2QhcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGmwY4XiZZRm\CCob4KgOUBl[Xm\|IHL5JG1VXCCjc4PhfUwhTUN3MDC9JFAvODJizszNMi=>	NH71doo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUOyOFU3Oid-M{GzNlQ2PjJ:L3G+
TZM-b1	NX7aeJlXSW62aY\pdoFtKGG\|c3H5		MV:xJIhz	NInLTGZCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZvMTDOUFQvOyCrbn\lZ5Rm\CCrbjDoeY1idiCWWl2tZlEh[2WubIOgdJJmfHKnYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgNkBl[Xm\|IHL5JGNRWkdiYYPzZZktKEmFNUCgQUAxNjB{MTFOwG0v	MnzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MEiyNlQoRjJ6NEC4NlI1RC:jPh?=
CEM-SS	NUiyN2pwSW62aY\pdoFtKGG\|c3H5		M2PaOVYh\GG7cx?=	NEXXNW9CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGNGVS2VUzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDh[pRmeiB4IHThfZMh[nliTWTTJIF{e2G7LDDFR\|UxKD1iMD6wNlMh\|ryPLh?=	M3;KZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkizNlYyLz5{N{K4N\|I3OTxxYU6=
HeLa	M{C1TWFvfGm4aYLhcEBie3OjeR?=		MUGzJIRigXN?	MVXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEh[2WubIOg[ZhxemW\|c3nu[{BETDRvTGTSMYJmfGFvZ3HsJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiMzDkZZl{KGK7IILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTBiPTCwMlAzOzZizszNMi=>	Mk[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OESyO\|AoRjJ2Nki0NlcxRC:jPh?=
HeLa-CD4-LTR-beta-gal	NXrYNI9WSW62aY\pdoFtKGG\|c3H5			NUHCdGF[SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYLUGgN2IhcW6oZXP0[YQhcW5iaIXtZY4hUGWOYT3DSFQuVFSULXLleIEu\2GuIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[nliU4DlZ5Rz[U2jeDDHSW1KVklvWGOgdIxifGVicnXh[IVzKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMkO2JO69VS5?	M1jv[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[xPVYxLz5{NUm2NVk3ODxxYU6=
HeLa	NEHXZnlCdnSrdnnyZYwh[XO\|YYm=		NHf0[WUzKGSjeYO=	NE\ZeIFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIEPCJIlv\mWldHXkJIlvKGi3bXHuJGhmVGFiY3XscJMh\XiycnXzd4lv\yCFRESgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDh[pRmeiB{IHThfZMh[nliYnX0ZU1o[WyjY4Tvd4ll[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTBiPTCwMlAzPCEQvF2u	M2\VXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK0PVE6Lz5{NEGyOFkyQTxxYU6=
MT-4	MXXBcpRqfmm{YXygZZN{[Xl?			NUHnO29lSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYIEGgVmlPKEiLVjCxJHJKViCqYYLic5JqdmdiaX70[Ydz[XOnIHflcoUhcW6oZXP0[YQhcW5iTWStOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7IHHmeIVzKDRyIIDhd5Ni\2W\|IIPlcIVkfGWmIHnuJJBz\XOnbnPlJI9nKGOxbYDveY5lNCCHQ{WwJF0hOC5yMkWg{txONg>?	M3fpU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{e4O\|E{Lz5zOEO3PFcyOzxxYU6=
TZM-bl	MV;BcpRqfmm{YXygZZN{[Xl?		MlXjOFghcHK\|	NEfQW3BCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiaX7m[YN1\WRiaX6gbJVu[W5iVGrNMYJtKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHnueoVzfGWmIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nzMEBGSzVyIE2gNE4xOjVizszNMi=>	NITBbGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1OFc3Oid-MkKxOVQ4PjJ:L3G+
MT4	Mon1SpVv[3Srb36gZZN{[Xl?		NX;xS3E2OSCqch?=	M4Xhb2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFjJWlEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IIXzbY5oKGOnbHzzJJBz\S2rbnP1ZoF1\WRid3n0bEBkd22yb4Xu[EBnd3JiMTDodkBu\WG\|dYLl[EA1KGSjeYOgdI9{fCC4aYLhcEBqdm[nY4Tpc44hcW5icILld4Vv[2Vib3[gNlAhdWdxbXygTHNCKGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFI6KM7:TT6=	M4r2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[zNVM2Lz5{Mkm2N\|E{PTxxYU6=
P4R5 MAGI	NVHn[YZRSW62aY\pdoFtKGG\|c3H5		MoLhNlQhcHK\|	MV3BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGmwZnXjeIVlKGmwIFPEOE9EYEOUND;DR3I2KGW6cILld5NqdmdiaIXtZY4hWDSUNTDNRWdKKGOnbHzzJJBz\WmwY4XiZZRm\CC5aYToJINmdGy\|IH\vdkAzPCCqcoOg[o9tdG:5ZXSgZpkhfmm{YXygbY5n\WO2aX;uJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvODNizszNMi=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB\|MUm3Okc,OzByM{G5O\|Y9N2F-
P4R5	MUDBcpRqfmm{YXygZZN{[Xl?		NWXjelJUOjRiaILz	NYf1ToN5SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDpcoZm[3SnZDDpckBETDRxQ2jDVlQwS0OUNTDlfJBz\XO\|aX7nJIh2dWGwIGC0VlUh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDwdoVqdmO3YnH0[YQhf2m2aDDj[YxteyCob4KgNlQhcHK\|IH\vcIxwf2WmIHL5JJZqemGuIHnu[oVkfGmxbjDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nliYnX0ZU1o[WyjY4Tvd4ll[XOnIILldI9zfGW{IHflcoUh[XO\|LDDFR\|UxKD1iMD6wN{DPxE1w	NWHkWpZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NlUzPzlpPkK4OVI2Ojd7PD;hQi=>
P4R5	Mk[1RY51cX[rcnHsJIF{e2G7		M{jzcVI1KGi{cx?=	M2\mfGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gbJVu[W5iUETSOUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5idnnyZYwhcW6oZXP0bY9vKHC{ZXnuZ5Vj[XSnZDD3bZRpKGOnbHzzJIZweiB{NDDodpMh\m:ubH;3[YQh[nlidnnyZYwhcW6oZXP0bY9vKG2nYYP1doVlKGGodHXyJFQ5KGi{czDifUBndHWxcnXzZ4Vv[2ViYnHz[YQh[mW2YT3nZYxi[3Sxc3nkZZNmKHKncH;yeIVzKGenbnWgZoF{\WRiTVHHTUBieyxiRVO1NEA:KDBwMEOg{txONg>?	NVjOe5ZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwN\|ExPjJpPkK5NFMyODZ{PD;hQi=>
P4R5	M2nUd2FvfGm4aYLhcEBie3OjeR?=		NEDZdm0zPCCqcoO=	MVLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYuOSCrbn\lZ5Rm\CCrbjDoeY1idiCSNGK1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC4aYLhcEBz\XCuaXPheIlwdiCycnXpcoN2[mG2ZXSg[o9zKDJ2IHjyd{Bnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44h[W6mIH3lZZN2emWmIHHmeIVzKDR6IHjyd{BjgSCPQVfJJIF{e2G7LDDFR\|UxKD1iMD6wN{DPxE1w	M3\ncFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyN{O5PFIzLz5\|MEezPVgzOjxxYU6=
P4R5	M{LGN2FvfGm4aYLhcEBie3OjeR?=		M2PnUFI1KGi{cx?=	NWrjVY9WSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDpcoZm[3SnZDDpckBpfW2jbjDQOHI2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjD2bZJ2eyC{ZYDsbYNifGmxbjDwdoVqdmO3YnH0[YQhf2m2aDDj[YxteyCob4KgNlQhcHK\|IH\vcIxwf2WmIHL5JJZqemGuIHnu[oVkfGmxbjDmc5IhPDhiaILzJIJ6KDRvbXX0bJltfW2kZXzsbYZmenmuZ3HsZYN1d3OrZHWtZoF{\WRiTVHHTUBie3OjeTygSWM2OCB;IECuNFMh\|ryPLh?=	Ml;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{OEOyOlEoRjJ5MkizNlYyRC:jPh?=
MT4	MX;BcpRqfmm{YXygZZN{[Xl?			MXjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnuJIh2dWGwIF3UOEBk\WyuczDpckBxemW\|ZX7j[UBw\iB3MDWgco9zdWGuIHj1cYFvKHOncoXtMEBKSzl3IE2gNE4xOzFizszNMi=>	M{G2R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{[zO\|UyLz5zOEe2N\|c2OTxxYU6=
MT4	MoK4RY51cX[rcnHsJIF{e2G7		MlnDOFghfG9iN{KgbJJ{	M1TOOWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHX4dJJme3OrbnegS2ZRKGmwY4XiZZRm\CCob4KgOFghfG9iN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJFUxLSCwb4LtZYwhcHWvYX6gd4VzfW1iYomgcZVtfGmybHWgdo92dmRidnnyZYwhemWybHnjZZRqd25ia3nu[ZRq[3NiYYPzZZktKEmSIE2gNE4xPTNizszNMi=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7N{m2OUc,OjZ\|OUe5OlU9N2F-
BL21(DE3)	NGnvW2tHfW6ldHnvckBie3OjeR?=		NGj2SlkyKGi{	NXTzdo1xUW6qaXLpeIlwdiCxZjDMSWRITi:yN{Wt[IVx\W6mZX70JIZ2dGxibHXu[5RpKEiLVj2xJIlvfGWpcnHz[UBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxLGRGOyliY3XscJMheHKnaX7jeYJifGWmIH\vdkAyKGi{IH\1dpRp\XJiaX7jeYJifGWmIH\vdkA6OCCvaX7zJJdqfGhiYnnveIlvNWyjYnXs[YQh\G:wb4KgSG5CKGGwZDD0ZZJo\XRiRF7BJIJ6KEiWUl[gZZN{[XluIFnDOVAhRSByLkC1PEDPxE1w	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTR2Mk[4OEc,OzF2NEK2PFQ9N2F-
MT-4	MXvBcpRqfmm{YXygZZN{[Xl?			NV\JTJY3SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYIEGgVmlPKEiLVjCxJHJKViCqYYLic5JqdmdiaX70[Ydz[XOnIHflcoUhcW6oZXP0[YQhcW5iTWStOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{NWmwZIXj[YQh[3m2b4DheIhq[yCnZn\lZ5Qh[nliTWTUJIF{e2G7IHHmeIVzKDZyIIDhd5Ni\2W\|IIPlcIVkfGWmIHnuJJBz\XOnbnPlJI9nKGOxbYDveY5lNCCHQ{WwJF0hOC5yNkig{txONg>?	NGnQc3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO3PFcyOyd-MUizO\|g4OTN:L3G+
HeLaT4	MkK4RY51cX[rcnHsJIF{e2G7			Mn[1RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4lv\2ynLYLveY5lKEiLVkGgUmxZNky3eD3SJIhiemKxcnnu[{BqdmGldHn2ZZRqdmdibYX0ZZRqd26\|IHnuJIVvfixidoDyJIFv\CClYYLybYV{KG[rcnXmcJkhdHWlaX\ldoF{\SCpZX7lJIlvKHCuYXPlJI9nKG6nZjDhd5Nme3OnZDDhd{Bt\X[nbDDv[kAzKG2rboOgcYFodmW2aXOgcoFvd3CjcoTpZYx{NW2nZHH0[YQhcW6oZXP0bY9vKGmwIHj1cYFvKEinTHHUOEBk\WyuczD0doVifGWmIH\vdkAyNCCHQ{mxJF0hOC5yN{Og{txONg>?	NXnmVHpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOlAyODhpPkKxNFYxOTB6PD;hQi=>
HeLa-T4	NVrs[oRDSW62aY\pdoFtKGG\|c3H5		M2nwR\|Q5KGi{cx?=	NY\3e2hVSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qhe2mwZ3zlMZJwfW6mIFjJWlEhVky[Llz1fE1TKGijcnLvdolv\yCrbnHjeIl3[XSrbnegcZV1[XSrb37zJIlvKGWwdjygepBzKGGwZDDjZZJzcWW\|IH\pdoVndHlibIXjbYZmemG\|ZTDn[Y5mKGmwIIDsZYNmKG:oIH7l[kBqdm[nY4Tl[EBqdiCqdX3hckBJ\UyjLWS0JINmdGy\|IHHzd4V{e2WmIHHzJIx2[2moZYLhd4Uh[WO2aY\peJkh[W[2ZYKgOFghcHK\|IHL5JIV5d2enbn;1d{BTXCCjc4PhfUwhTUN3MDC9JFAvODd5IN88UU4>	MluyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyNkCxNFgoRjJzME[wNVA5RC:jPh?=
TZM-bl	NWC3dXlKSW62aY\pdoFtKGG\|c3H5		M4Tyc\|Q5KGi{cx?=	MVTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYuOSCrbn\lZ5Rm\CCrbjDoeY1idiCWWl2tZowh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDmc5IhPDhiaILzJIJ6KGK{aXfoeE1IdG9ibIXjbYZmemG\|ZTDhd5NigSxiRVO1NEA:KDBwMUWg{txONg>?	MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2OEe5NVMoRjJ4NEi3PVE{RC:jPh?=
HOS	NF\WXnZCdnSrdnnyZYwh[XO\|YYm=		NETZZ2c{KGi{cx?=	MofnRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKGijcnLvdolv\yCrboTl[5Jie2ViTkG1OWghdXW2YX70JIlv\mWldHXkJIlvKEiRUzDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KH[rcnHsJIlv\mWldHnvckBu\WG\|dYLl[EBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwJF0hOC5zNUSg{txONg>?	NFjJNmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVgyPid-MkS0O\|E5OTZ:L3G+
TZM-bl	MlzORY51cX[rcnHsJIF{e2G7			NUmwO29sSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQvOyCrbn\lZ5Rm\CCrbjDoeY1idiCWWl2tZowh[2WubIOgcYVie3W{ZXSgeZB1dyB{NDDodpMh[nliYoLp[4h1KEeubz3seYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjF4IN88UU4>	NIjyTG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUW1O\|YxQSd-M{G1OVc3ODl:L3G+
HOS	M37td2FvfGm4aYLhcEBie3OjeR?=		M2foW\|MhcHK\|	M4ThR2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCqYYLic5JqdmdiaX70[Ydz[XOnIGmxOFNTKG23dHHueEBqdm[nY4Tl[EBqdiCKT2OgZ4VtdHNicILlbY5kfWKjdHXkJIZweiB\|IHjyd{Bnd2yub4fl[EBjgSC4aYLhcEBqdm[nY4Tpc44hdWWjc4Xy[YQh[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMU[yJO69VS5?	NXz1d282RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E5OTZpPkK0OFcyQDF4PD;hQi=>
TZM-bl	NILVTZhCdnSrdnnyZYwh[XO\|YYm=		MnXENUBpeg>?	M1GyfGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTly0MlMhcW6oZXP0[YQhcW5iaIXtZY4hXFqPLXLsJINmdGy\|IHX4dJJme3OrbnegR3hEWjRvdILvdIlkKGmwY4XiZZRm\CCob4KgNUBpeiCycnnvdkB1dyCrbn\lZ5Rqd25ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuOUDPxE1w	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7MUC0Nkc,OjR{OUGwOFI9N2F-
TZM-bl	MmfhRY51cX[rcnHsJIF{e2G7		Mkj2NUBpeg>?	MmHmRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTESuN{Bqdm[nY4Tl[EBqdiCqdX3hckBVYk1vYnygZ4VtdHNiZYjwdoV{e2mwZzDDXGNTPC22cn;wbYMhcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJJRwKGmwZnXjeIlwdiCvZXHzeZJm\CCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR\|UxKD1iMD61NFEyQSEQvF2u	NUThOYZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVExPDJpPkK0NlkyODR{PD;hQi=>
HeLa-T4	M2HBRmFvfGm4aYLhcEBie3OjeR?=		NVfJ[pgyPDhiaILz	NFjkfYtCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB{cW6pbHWtdo92dmRiSFnWNUBPVFhwTIX4MXIhcGG{Yn;ybY5oKGmwYXP0bZZifGmwZzDteZRifGmxboOgbY4h\W64LDD2dJIh[W6mIHPhdpJq\XNiZnny[YZtgSCudXPp[oVz[XOnIHflcoUhcW5icHzhZ4Uhd2ZibnXmJIlv\mWldHXkJIlvKGi3bXHuJGhmVGFvVESgZ4VtdHNiYYPz[ZN{\WRiYYOgcJVkcW[ncnHz[UBi[3Srdnn0fUBi\nSncjC0PEBpenNiYomg[Zhw\2Wwb4XzJHJVKGG\|c3H5MEBGSzl3IE2gNE45OSEQvF2u	M{XUeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzME[wNVA5Lz5{MUC2NFExQDxxYU6=
HOS	NEL4ellCdnSrdnnyZYwh[XO\|YYm=		NFW4XYI{KGi{cx?=	NYDQNZM2SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUHWvYX6gbY1ufW6xZHXmbYNq\W6leTD2bZJ2eyBzIHjhdoJwemmwZzDpcpRm\3Kjc3WgS\|E1OFNxUUG0PGgh\G:3YnzlJI12fGGwdDDpcoZm[3SnZDDpckBJV1NiY3XscJMheHKnaX7jeYJifGWmIH\vdkA{KGi{czDmc4xtd3enZDDifUB3cXKjbDDpcoZm[3Srb36gcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFEvQSEQvF2u	MkKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G4NVYoRjJ2NEexPFE3RC:jPh?=
MT2	MXXBcpRqfmm{YXygZZN{[Xl?		Mo\BN{B1dyB2IHThfZM>	NXzaZmk3SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQuOyCqYYLic5JqdmdiR{G0NHMwWTF2OFigcZV1[W62IHnu[oVkfGWmIHnuJIh2dWGwIF3UNkBk\WyuczDt[YF{fXKnZDDh[pRmeiB\|IITvJFQh\GG7czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSB{LkSyJO69VS5?	NHXOXYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MkC4NVAyOCd-M{KwPFExOTB:L3G+
HeLaT4	MX;BcpRqfmm{YXygZZN{[Xl?		MUGyOEBpenN?	NHroNlBCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB{cW6pbHWtdo92dmRiSFnWNUBPVFhwTIX4MXIhcGG{Yn;ybY5oKGmwYXP0bZZifGmwZzDteZRifGmxboOgbY4h\W64LDD2dJIh[W6mIHPhdpJq\XNiZnny[YZtgSCudXPp[oVz[XOnIHflcoUhcW5icHzhZ4Uhd2ZibnXmJIF{e2W\|c3XkJIF{KGyndnXsJI9nKGmwZnXjeIlwdiC3c3nu[{BpfW2jbjDI[WxiXDRiY3XscJMheHKndILlZZRm\CCob4KgNlQhcHK\|IH\vcIxwf2WmIHL5JIV5eG:\|ZXSgeI8hfmluIFXDOVAhRSB2Lk[g{txONg>?	Ml\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyNkCxNFgoRjJzME[wNVA5RC:jPh?=
MT4	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		MofNOUBl[Xm\|	NEmxU3lEgXSxdH;4bYNqfHliaX6gcY9kcy2rbn\lZ5Rm\CCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPSCmYYnzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDZwNUGg{txONg>?	NGfZUmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUOyOFU3Oid-M{GzNlQ2PjJ:L3G+
CHO	NIC3c4VHfW6ldHnvckBie3OjeR?=			MmC3TY5pcWKrdHnvckBw\iC\|bH;3JIRmdGG7ZXSgbY54[XKmIILlZ5Rq\nmrbnegdI91[XO\|aYXtJIN2enKnboSgLGlseyliaX6gR4hqdmW\|ZTDIZY1{fGW{IF;2ZZJ6KCiFSF:pJINmdGy\|IHX4dJJme3OrbnegbGt3VFGWMT;ocYlvUyCvZXHzeZJm\CC3c3nu[{BKd26Zb4Lrd{BSfWG2dILvJIF2fG:vYYTl[EBx[XSlaDDjcIFueCCybHH0[o9zdSxiSVO1NEA:KDJ3LkGxPFkh\|ryPLh?=	NWnUV4JsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFc4PTNpPkK1NFg4PzV\|PD;hQi=>
U373-MAGI	NF;4T4xCdnSrdnnyZYwh[XO\|YYm=	MV61NEBweiBzMECgcm0>	NF:5bpg4OiCqcoO=	MnPPRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDnZYchdGW4ZXygZZQhPTBib4KgNVAxKG6PIH3lZZN2emWmIHH0JFczKGi{czDwc5N1KGmwZnXjeIlwdiCkeTDxVGNTKG2ndHjv[C=>	NGfQPVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+
U373-MAGI	NUP3TXg2SW62aY\pdoFtKGG\|c3H5	NV:5Vop7PTBib4KgNVAxKG6P	M3LBPFczKGi{cx?=	M1ntPWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV\|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gWVUu\2GpIHzleoVtKGG2IEWwJI9zKDFyMDDuUUBu\WG\|dYLl[EBifCB5MjDodpMheG:\|dDDpcoZm[3Srb36gZpkheVCFUjDt[ZRpd2R?	NVf4V\|dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
MT2	NGmwUHdCdnSrdnnyZYwh[XO\|YYm=	MVqxJJVO	NXT3OZNKOzBiaILz	NFrqZ\|BCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymLYT5dIUhUEmYMTDOUFQuOyCrbn\lZ5Rm\CCrbn\lZ5Rm\CCrbjDoeY1idiCPVEKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEiLVkGgbY51\We{YYTl[EBFVkFiYYSgNUB2VSCjbnSgcYVie3W{ZXSgZYZ1\XJiM{CgbJJ{KHCxc4SgbY5n\WO2aX;uJIJ6KEGudT3MWHIhWEOUIIDyc5Rw[2:uIHLhd4VlKG2ndHjv[C=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl7Nke4NEc,OzB7OU[3PFA9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CHOP / ATF-4 / XBP-1 / Lamin B; PubMed: 24625618 PLoS One Mouse J774A.1 cells were treated with different concentrations of raltegravir (0, 5, 15, 25 or 50 µM) in the absence or presence of ritonavir (RITV, 25 µM) or thapsigargin (TG, 100 nM), a known ER stress inducer, for 4 h, and the nuclear proteins were iso䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뾠Ղ䐺痖暼瘿뾠Ղᾰƌ 뾠ՂÐ㺣痖뾠Ղ𢡄	24625618

In vivo

Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse PFV integration assay: For quantitative strand transfer assays, donor DNA substrate is formed by annealing HPLC grade oligonucleotides 5′-GACTCACTATAGGGCACGCGTCAAAATTCCATGACA and 5′-ATTGTCATG GAATTTTGACGCGTGCCCTATAGTGAGTC. Reactions (40 μL) contains 0.75 μM PFV IN, 0.75 μM donor DNA, 4 nM (300 ng) supercoiled pGEM9-Zf(−) target DNA, 125 mM NaCl, 5 mM MgSO₄, 4 μM ZnCl₂, 10 mM DTT, 0.8% (vol/vol) DMSO, and 25 mM BisTris propane–HCl, pH 7.45. Raltegravir is added at indicated concentrations. Reactions are initiated by addition of 2 μL PFV IN diluted in 150 mM NaCl, 2 mM DTT, and 10 mM Tris-HCl, pH 7.4, and stopped after 1 hour at 37 °C by addition of 25 mM EDTA and 0.5% (wt/vol) SDS. Reaction products, deproteinized by digestion with 20 μg proteinase K for 30 minutes at 37 °C followed by ethanol precipitation, are separated in 1.5% agarose gels and visualized by staining with ethidium bromide. Integration products are quantified by quantitative real-time PCR, using Platinum SYBR Green qPCR SuperMix and three primers: 5′-CTACTTACTCTAGCTTCCCGGCAAC, 5′-TTCGCCAGTTAATAGTTTGCGCAAC, and 5′-GACTCACTATAGGGCACGCGT. PCR reactions (20 μL) contained 0.5 μM of each primer and 1 μL diluted integration reaction product. Following a 5-min denaturation step at 95 °C, 35 cycles are carried out in a CFX96 PCR instrument, using 10 seconds denaturation at 95 °C, 30 seconds annealing at 56 °C and 1 minutes extension at 68 °C. Standard curves are generated using serial dilutions of WT PFV IN reaction in the absence of INSTI.
Cell Research: ^[5]	- Collapse Cell lines: Human MT-4 cells Concentrations: 0.0001-1 μM Incubation Time: 5 days Method: Human MT-4 cells are infected for 2 hours with the SIVmac251, HIV-1 (IIIB) and HIV-2 (CDC 77618) stocks at a multiplicity of infection of, approximately, 0.1. Cells are then washed three times in phosphate buffered saline, and suspended at 5 × 10⁵/mL in fresh culture medium (to primary cells 50 units/mL of IL-2 are added) in 96-well plates, in the presence or absence of a range of triplicate raltegravir concentrations (0.0001 μM -1 μM). Untreated infected and mock-infected controls are prepared too, in order to allow comparison of the data derived from the different treatments. Viral cytopathogeniciy in MT-4 cells is quantitated by the methyl tetrazolium (MTT) method (MT-4/MTT assay) when extensive cell death in control virus-infected cell cultures is detectable microscopically as lack of capacity to re-cluster. The capability of MT-4 cells to form clusters after infection. Briefly, clusters are disrupted by pipetting; and, after 2 hours of incubation at 37 °C, the formation of new clusters is assessed by light microscopy (100 × magnification). Cell culture supernatants are collected for HIV-1 p24 and HIV-2/SIVmac251 p27 core antigen measurement by ELISA. In CEMx174-infected cell cultures, which show a propensity to form syncytia induced by the virus envelope glycoproteins, syncytia are counted, in blinded fashion, by light microscopy for each well at 5 days following infection. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: Indian Rhesus macaques Dosages: 50 mg/kg or 100 mg/kg Administration: Oral administration (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	88 mg/mL (198.01 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+40% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Raltegravir (MK-0518) SDF

Molecular Weight	444.42
Formula	C₂₀H₂₁FN₆O₅
CAS No.	518048-05-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04513626	Recruiting	Drug: DORAVIRINE 100 MG [Pifeltro]	HIV Infections	Centre de Recherches et d''Etude sur la Pathologie Tropicale et le Sida	September 15 2020	Phase 2
NCT03667547	Completed	Drug: Raltegravir	Human Immunodeficiency Virus (HIV) Infection	Merck Sharp & Dohme Corp.	September 27 2018	Phase 4
NCT03174977	Recruiting	Drug: 18F-Raltegravir	HIV-1-infection	University of California San Francisco\|Merck Sharp & Dohme Corp.	April 1 2018	Early Phase 1
NCT03205566	Completed	Drug: Raltegravir 400Mg Tab\|Drug: Lamivudine 150Mg Tablet	Hiv	Guy''s and St Thomas'' NHS Foundation Trust	September 19 2017	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Integrase Signaling Pathway Map

Related Integrase Products

Cabotegravir (GSK1265744) ^New

Cabotegravir (GSK744, GSK1265744, S/GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.
Tenofovir Alafenamide (GS-7340) ^New

Tenofovir Alafenamide (GS-7340) is a prodrug of tenofovir, which is a reverse transcriptase inhibitor, used to treat HIV and Hepatitis B.
Elvitegravir (JTK-303)

Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.
BMS-707035

BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.
Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572, S/GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Features:A next-generation and two-metal-binding HIV integrase strand transfer inhibitor.
MK-2048

MK-2048 is a potent inhibitor of integrase (IN) and IN_R263K with IC50 of 2.6 nM and 1.5 nM, respectively.
Maraviroc (UK-427857)

Maraviroc (UK-427857) is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV infection.
Tenofovir (GS 1278) Disoproxil Fumarate

Tenofovir Disoproxil Fumarate (GS-1278, Tenofovir DF) belongs to a class of antiretroviral drugs, it inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination.
Zidovudine

Zidovudine (ZDV, Azidothymidine, NSC 602670) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. It could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.

Choose Your Country or Region

By Signaling Pathways

By product type

Raltegravir (MK-0518)